№ lp_1_2_28283
File format: docx Character count: 149755 File size: 1215 KB
This document outlines a submission to the PBS for the approval of Dabrafenib and Trametinib for paediatric patients with BRAF V600E mutation-positive gliomas, presenting clinical data and requested restrictions for listing.
Year: 2023
Region / City: Australia
Theme: Paediatric Oncology, Pharmacology
Document Type: Medical Submission
Organization / Institution: Novartis Pharmaceuticals Australia Pty Limited
Author: Novartis Pharmaceuticals Australia Pty Limited
Target Audience: Medical practitioners, oncologists, pharmacists, healthcare providers
Period of Validity: Not specified
Approval Date: 6 December 2023
Date of Amendments: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplementary Figure 9. Distribution of immune features of M2 macrophages, TGF-β, plasma cells, and memory activated CD4+ T cells by BRAF V600E
Year: Not specified
Region / City: Not specified
Subject: Immune features, BRAF V600E mutation
Document type: Scientific figure
Author: Not specified
Target audience: Researchers in immunology
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Topics: Dabrafenib Trametinib V600E